Jeffrey Leiden

Leiden grew up in Glencoe, a suburb north of Chicago. His mother was a primary school teacher, and his father was a clinical psychologist with a PhD in psychology. He has one sister. His grandparents on his mother’s side were Russian immigrants. At ten years old he learned to scuba dive, and by eleven he was a certified scuba instructor.{{Cite journal|date=2018-03-06|title=First Rounders podcast: Jeffrey Leiden|journal=Nature Biotechnology|language=en|volume=36|issue=3|pages=224|doi=10.1038/nbt.4087|pmid=29509728|issn=1546-1696|doi-access=free}}

Leiden attended a progressive public school in Glencoe, IL called North School which had a special self-paced learning program. In elementary school Leiden skipped second grade and started the University of Chicago after his junior year at New Trier East High School, at the age of 15.

He received his bachelor's degree in biological sciences at age 18, a Ph.D. in virology at age 21 and his M.D. at age 23 from the University of Chicago, where he later became Chief of Cardiology.{{cite web| url =http://www.chicagobusiness.com/article/19940924/ISSUE01/100011230/jeffrey-m-leiden-section-chief-of-cardiology-university-of-chicago-medical-center|author= Arsenio Oloroso Jr.|title=Jeffrey M. Leiden Section Chief of Cardiology University of Chicago Medical Center |publisher=Crain's Chicago Business|date =September 24, 1994}} He was elected to several honors societies, including Phi Beta Kappa and Alpha Omega Alpha.{{Cite web|url=https://issuu.com/medicineonthemidway/docs/medicineonthemidway-spring2019/14|title=Medicine on the Midway – Spring 2019|website=issuu|access-date=2019-07-02}} Between 1982 and 1987, Leiden was a clinical fellow in cardiology at the Brigham and Women’s Hospital,the Harvard Medical School and a postdoctoral fellow in medicine at the Dana–Farber Cancer Institute.{{cite web| url =https://www.bloomberg.com/research/stocks/private/person.asp?personId=247509&privcapId=36235|title=Executive Profile Jeffrey Marc Leiden |publisher=Bloomberg L.P.|accessdate =May 11, 2018}}

In 1987, Leiden was appointed assistant professor of medicine and assistant investigator in the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor.{{cite journal| url =https://www.science.org/doi/10.1126/science.1962203|title=Putting new muscle into gene therapy|journal=Science|date =December 6, 1991|doi=10.1126/science.1962203 |last1=Hoffman |first1=Michelle |volume=254 |issue=5037 |pages=1455–1456 |pmid=1962203 |bibcode=1991Sci...254.1455H }}

In 1992, Leiden moved to the University of Chicago as the Rawson Professor of Medicine and Pathology and chief of the Division of Cardiology.{{cite web| url =https://www.fiercebiotech.com/special-report/jeffrey-leiden-vertex-pharmaceuticals|author=Emily Mullin|title=Jeffrey Leiden—Vertex Pharmaceuticals|publisher=FierceBiotech|accessdate =May 10, 2018}}

In 1996, Leiden, along with Elizabeth and Gary Nabel founded Cardiogene, a gene therapy company, which was subsequently acquired by Boston Scientific.{{cite web| url =https://www.biocentury.com/biocentury/emerging-company-profile/1997-09-29/ins-and-outs-cardiovascular-gene-therapy-cardiogene|title=Ins and Outs of Cardiovascular Gene Therapy; Cardiogene: The Insuide; Eurogene: The Outside|publisher=BioCentury|date =September 29, 1997}}

In 1999, Leiden was appointed the Elkin Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of medicine at the Harvard Medical School.

Leiden moved to Abbott Labs in June 2000, as senior vice president and chief scientific officer. Later that year, he was promoted to president and chief operating officer and oversaw all aspects of the company’s global pharmaceutical business, where he led the development and launch of Kaletra and Humira.{{cite web| url =https://www.medscape.com/viewarticle/784035|title=Harvard cardiologist Jeffrey Leiden elected new chief scientific officer at Abbott Laboratories|publisher=Medscape|date =June 16, 2000}}{{cite web| url =https://www.vrtx.com/leadership/jeffrey-leiden-md-phd|title=Jeffrey Leiden, M.D., Ph.D.|publisher=Vertex Pharmaceuticals|accessdate =May 10, 2018}}

In 2006, Leiden joined Clarus Ventures as a managing director.{{cite web| url =https://www.biospace.com/article/releases/-b-dr-jeffrey-leiden-b-joins-b-clarus-ventures-b-as-partner-/|title=Dr. Jeffrey Leiden Joins Clarus Ventures As Partner|publisher=Biospace|date =November 1, 2006 }} At Clarus, Leiden founded and chaired the boards of Lycera Corporation and Variation Biotechnologies, and served as chairman of the board of TyRx, Inc., which was subsequently acquired by Medtronic ({{NYSE|MDT}}).{{cite web| url =http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=189860|title= Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors|publisher=Evaluate|date =July 7, 2009}}

Leiden served as chairman, president and chief executive officer of Vertex from 2012 to 2020. Under his leadership, Vertex developed and launched Kalydeco, Orkambi, Symdeko and Trikafta – the first medicines to treat the underlying cause of cystic fibrosis.{{cite web| url =https://www.forbes.com/sites/matthewherper/2017/08/08/vertex-pharmaceuticals-and-the-price-of-inspiration/#52336af05de1|author=Matthew Herper|title=For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?|work=Forbes|date =August 8, 2017}} The FDA approved Trikafta on October 21, 2019.{{Cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis|title=FDA approves new breakthrough therapy for cystic fibrosis|last=Commissioner|first=Office of the|date=2019-10-24|website=FDA|language=en|access-date=2019-10-25}}

In 2015 Leiden established a collaboration between Vertex and CRISPR Therapeutics that led to the discovery and development of Casgevy, (exagamglogene autotemcel; formerly known as CTX001),{{cite news |last1=Shapiro |first1=Lindsey |title=Casgevy (exagamglogene autotemcel) for sickle cell disease |url=https://sicklecellanemianews.com/ctx001-sickle-cell-disease |publisher=Sickle Cell Disease News |date=17 May 2024}} the first gene editing treatment to show curative potential for two human genetic diseases, sickle cell disease and beta thalassemia.{{Cite web|title=1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive|url=https://www.npr.org/sections/health-shots/2020/12/15/944184405/1st-patients-to-get-crispr-gene-editing-treatment-continue-to-thrive|access-date=2021-02-23|website=NPR.org|language=en}}{{Cite web|date=2019-11-20|title=Vertex reveals promising data from first CRISPR-treated patients|url=http://www.pmlive.com/pharma_news/vertex_reveals_promising_data_from_first_crispr-treated_patients_1317564|access-date=2021-02-23|website=PMLive|language=en}}{{Cite web|last=Smith|first=Jonathan|date=2019-06-07|title=CRISPR Therapeutics and Vertex Pharmaceuticals Seal Deal Worth up to €890M|url=https://www.labiotech.eu/trends-news/crispr-therapeutics-vertex-dystrophy/|access-date=2021-02-23|website=Labiotech.eu|language=en-US}} Casgevy was approved for use in the UK (November 2023), the United States (January 2024) and Europe, (February 2024.){{cite news | vauthors = Barrie R |title=CRISPR gene therapy Casgevy secures approval in Europe |url=https://www.pharmaceutical-technology.com/news/crispr-gene-therapy-casgevy-secures-approval-in-europe/ |publisher=Pharmaceutical Technology |date=13 February 2024}}

In 2015 Vertex shareholders voted to recommend reducing Leiden's compensation from its 2014 estimated figure of US$48.5 million. By 2017 his earnings totaled approximately US$17.3 million.{{Cite news|url=https://www.reuters.com/article/brief-vertex-pharma-ceos-fy-2017-total-c-idUSFWN1RU16P|title=BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln|date=2018-04-17|work=Reuters|access-date=2019-05-29|language=en}} Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880.{{cite news |last1=Gelman |first1=Max |title=The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic |url=https://endpts.com/the-diabetes-cure-vertex-acquired-in-its-2019-semma-buyout-its-headed-to-the-clinic/ |publisher=Endpoints News |date=29 January 2021}}{{cite news |last1=Bell |first1=Jacob |title=Vertex begins human testing for diabetes cell therapy |url=https://www.biopharmadive.com/news/vertex-semma-human-testing-diabetes-cell-therapy/596466/ |publisher=BiopharmaDive |date=10 March 2021}}

Criticism of Vertex pricing structures for Orkambi, a groundbreaking cystic fibrosis drug costing in the region of {{Currency|amount=135000|code=}} to {{Currency|amount=270000|code=}}{{Cite news |last=Thomas |first=Katie |date=2018-06-24 |title=A Drug Costs $272,000 a Year. Not So Fast, Says New York State. |url=https://www.nytimes.com/2018/06/24/health/drug-prices-orkambi-new-york.html |access-date=2019-02-03 |work=The New York Times |language=en-US |issn=0362-4331}} per patient per year depending on the patient's country, has resulted in campaigns by concerned parent groups addressed to Leiden.{{Cite news | veditors = Boseley S |date=2019-02-03 |title=Cystic fibrosis: the patients facing shorter lives due to drug's expense |url=https://www.theguardian.com/society/2019/feb/03/cystic-fibrosis-patients-shorter-lives-orkambi-expense-nhs |access-date=2019-02-03 |work=The Guardian |language=en-GB |issn=0261-3077}}{{Cite web |title=CF Support Group {{!}} Letter to Dr Jeffrey Leiden |url=https://www.cfsupportgroup.org/letter-to-jeffrey-leiden |access-date=2019-02-03 |website=CF Support Group |language=en}} Leiden wrote to the UK Prime Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs.{{Cite web |title=Orkambi: Drugs maker says NHS 'undervalues' patient lives |url=https://news.sky.com/story/orkambi-drugs-maker-says-nhs-undervalues-patient-lives-11442845 |access-date=2019-02-03 |website=Sky News |language=en}}

On October 24, 2019, Vertex reached an agreement with NHS England for all currently licensed Vertex cystic fibrosis medicines,{{Cite web|url=https://www.pmlive.com/pharma_news/vertex,_nhs_england_and_nice_finally_reach_agreement_for_orkambi_1314406|title=Vertex, NHS England and NICE finally reach agreement for Orkambi|date=2019-10-24|website=PMLive|language=en|access-date=2019-10-25}}{{Cite web|url=https://www.statnews.com/pharmalot/2019/10/24/vertex-uk-cystic-fibrosis-drug-prices-deal/|title=Vertex and the U.K. reach a deal for cystic fibrosis medicines|date=2019-10-24|website=STAT|language=en-US|access-date=2019-10-25}}{{Cite news|url=https://www.bbc.com/news/health-47115039|title=Cystic fibrosis drug deadlock 'must end'|date=2019-02-04|access-date=2019-05-07|language=en-GB}} having previously reached similar agreements with countries including Scotland, Ireland and France.{{cite web |last1=Bruce |first1=Francesca |title=Vertex Inks New Cystic Fibrosis Deals In Europe |url=https://pink.pharmaintelligence.informa.com/PS144637/Vertex-Inks-New-Cystic-Fibrosis-Deals-In-Europe |website=Pink Sheet |access-date=3 April 2022}}{{cite web |title=Landmark NHS deal to open up access to life-changing cystic fibrosis drug |url=https://www.england.nhs.uk/2020/08/landmark-nhs-deal-to-open-up-access-to-life-changing-cystic-fibrosis-drug/ |website=NHS |access-date=3 April 2022}} On June 20, 2024, the National Institute for Health and Care Excellence, (NICE) said in its final draft guidance that Orkambi, Symkevi, and Kaftrio are recommended for the treatment of Cystic Fibrosis, with Vertex coming to a long-term, extended, reimbursement agreement{{cite news |last1=Manalac |first1=Tristan |title=Vertex Finally Reaches Pricing Deal With England’s NHS for Cystic Fibrosis Drugs |url=https://www.biospace.com/vertex-reaches-pricing-deal-with-england-s-nhs-for-cystic-fibrosis-drug |publisher=BioSpace |date=21 June 2024}} with the NHS.{{cite news |last1=Furlong |first1=Ashleigh |title=Vertex Reaches Pricing Deal With NHS for Cystic Fibrosis Drugs |url=https://www.bloomberg.com/news/articles/2024-06-20/vertex-reaches-pricing-deal-with-nhs-for-cystic-fibrosis-drugs |publisher=Bloomberg |date=20 June 2024}}{{cite news |last1=Silverman |first1=Ed |title=Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments |url=https://www.statnews.com/pharmalot/2024/06/20/vertex-uk-england-nhs-cystic-fibrosis-trikafta-medicines/ |publisher=STAT |date=20 June 2024}}{{cite news |last1=Inácio |first1=Patricia |title=3 CFTR modulators guaranteed public reimbursement in England |url=https://cysticfibrosisnewstoday.com/news/3-cftr-modulators-guaranteed-public-reimbursement-england/?utm_source=CF&utm_campaign=42ef24dcd0-Email_ENL_US_CF&utm_medium=email&utm_term=0_b075749015-42ef24dcd0-73637477 |publisher=Cystic Fibrosis News Today |date=26 June 2024}} This final decision differs from its provisional draft guidance from November 2023 that recommended that the three drugs were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis patients.{{Cite web | last=Lipanovic |first=David |date=2023-11-14 |title=NICE does not recommend three cystic fibrosis drugs in draft guidance |url=https://pharmaceutical-journal.com/article/news/nice-does-not-recommend-three-cystic-fibrosis-drugs-in-draft-guidance |access-date=2024-02-25 |website=The Pharmaceutical Journal |language=en-US}}

While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.{{cite news |title=How A Medical Brainiac CEO Turned Brilliance Into Billions |url=https://www.investors.com/news/management/leaders-and-success/vertex-ceo-how-jeffrey-leiden-turned-brilliance-into-billions/|last=Doler|first=Kathleen|date=16 July 2020}}

On April 1, 2020, Leiden transitioned to the role of executive chairman. He was succeeded by Reshma Kewalramani, who was previously the company's chief medical officer. Leiden currently serves as executive chairman.{{Cite web|url=https://www.bizjournals.com/boston/news/2019/07/25/vertex-ceo-jeff-leiden-to-step-down.html|title=Vertex CEO Jeff Leiden to step down|last=DeAngelis|first=Allison|date=25 July 2019|website=www.bizjournals.com|access-date=2019-07-31}}{{Cite web|url=https://endpts.com/vertexs-cmo-reshma-kewalramani-takes-ceo-post-as-longtime-vet-jeff-leiden-moves-to-new-role/|title=Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role|website=Endpoints News|language=en|access-date=2020-04-02}}{{cite web |title=Vertex Pharmaceuticals Incorporated Form 10-K |url=https://investors.vrtx.com/static-files/7bf5f528-b4ed-45c4-893d-bf9d98a53bb1 |access-date=3 April 2022}}

He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians.{{cite web| url =http://web.mit.edu/sloanhcc/bioinnovations/2013/speakers.html|title=Keynote Speakers |publisher=Massachusetts Institute of Technology|date =February 22, 2013 }}{{cite book |last=Pray |first=Leslie|isbn=9780309179768 |title=Understanding the Benefits and Risks of Pharmaceuticals |url=https://books.google.com/books?id=XSAPDqqMauQC&q=jeffrey+leiden+%22American+Society+of+Clinical+Investigation%22 |date=August 14, 2007|publisher=National Academies Press }} He currently serves as a lead independent director {{cite news |title=Corporate Governance |url=https://www.massmutual.com/about-us/corporate-governance |publisher=MassMutual |date=2024}} of the Massachusetts Mutual Life Insurance Company, and was the former vice chairman of Shire Pharmaceuticals and was formerly a director of PathAI, Millennium Pharmaceuticals, Abbott Labs, Quest Diagnostics, and TAP Pharmaceuticals.{{cite web|url=http://www.mass.edu/stem/home/councilmembers.asp#leiden |title=STEM Council Co-Chairs |publisher=Massachusetts Department of Higher Education|accessdate =May 20, 2018}} Leiden is also the chairman of Casana, a home health monitoring company.{{Cite web|last=Jennings|first=Katie|title=This Smart Toilet Seat Might Save Your Life One Day|url=https://www.forbes.com/sites/katiejennings/2021/02/03/this-smart-toilet-seat-might-save-your-life-one-day/|access-date=2021-02-11|website=Forbes|language=en}} In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease.{{cite web |title=Odyssey Therapeutics:News |url=https://odysseytx.com/news/|website=odysseytx.com/news |date=24 May 2022}}

Leiden was named a Crain’s Chicago Business 40 Under 40 in 1994; and served as a member of the NHLBI Board of Scientific Counselors between 1994 and 1999.{{cite web| url =https://www.chicagobusiness.com/article/20140709/PAGES/140709836/crain-s-chicago-business-40-under-40-historical-archive|publisher=Crain's Chicago Business |date=July 9, 2014|title=40 Under 40 historical archive}} In 2000, he was president of the American Society for Clinical Investigation.{{Cite web|url=https://www.the-asci.org/council_history.shtml|title=The American Society for Clinical Investigation|language=en-US|access-date=2019-07-15|archive-date=2017-03-17|archive-url=https://web.archive.org/web/20170317225634/https://www.the-asci.org/council_history.shtml|url-status=dead}}

In 2017, Ernst and Young named Leiden an Entrepreneur of the Year in Life Sciences.{{cite web| url =http://www.ey.com/us/en/newsroom/news-releases/news-ey-announces-winners-for-the-eoy-2017-new-england-award|title=EY Announces Winners for the Entrepreneur Of The Year® 2017 New England Award|publisher=Ernst & Young|date =June 28, 2017}} In 2018, the Massachusetts Biotechnology Council awarded Leiden the Henri A. Termeer Innovative Leadership Award; and the Greater Boston Chamber of Commerce named Leiden to the Academy of Distinguished Bostonians.{{cite web| url =https://www.massbio.org/news/blog/massbio-to-honor-dr-jeffrey-leiden-with-henri-a-termeer-innovative-leadership-award-141159 |title=MassBio to Honor Dr. Jeffrey Leiden with Henri A. Termeer Innovative Leadership Award|publisher=MassBio|date =March 6, 2018}}{{cite web| url =http://edition.pagesuite.com/popovers/article_popover.aspx?guid=04aa9ba6-94fb-48e2-9ae4-59dd08a90a49|publisher=Boston Globe |date =June 21, 2017|title=With $500m initiative, Baker is a biotech holdout no longer}} Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022.{{cite news |title=Meet the 2022 Boston Business Journal Power 50 Movement Makers |url=https://www.bizjournals.com/boston/news/2022/11/16/meet-the-2022-boston-business-journal-power-50-mov.html |publisher=Boston Business Journal |date=16 November 2022}}{{cite web| url =https://www.bizjournals.com/boston/news/2018/10/09/meet-the-2018-boston-business-journal-power-50.html|publisher=Boston Business Journal|date =October 9, 2018|title=Meet the 2018 Boston Business Journal Power 50 }} In 2018 and 2020, he was named as part of Boston Magazine’s 100 Most Influential People in Boston{{Cite web|title=Power List: The 100 Most Influential Bostonians|url=https://www.bostonmagazine.com/boston-power-2020/|website=Boston Magazine|date=28 April 2020 |access-date=2020-05-05}} and was honored as a New Englander of the Year by the New England Council.{{cite web| url =https://newenglandcouncil.com/blog-post/2018-new-englanders-of-the-year-announced/|publisher=The New England Council|accessdate =November 18, 2018|title=2018 New Englanders of the Year Announced}}{{cite web| url =https://www.bostonmagazine.com/news/2018/04/24/most-influential-people-boston/|publisher=Boston Magazine|date =April 24, 2018|title=The 100 Most Influential People in Boston}} In 2018 he was named “Best Biopharma CEO” by STAT News.{{Cite web|url=https://www.statnews.com/2018/12/18/leiden-victorious-in-best-biopharma-ceo-tally-alles-tops-worst-list/|title=Leiden victorious in best biopharma CEO tally; Alles tops worst list|date=2018-12-18|website=STAT|language=en-US|access-date=2019-07-02}} In December 2020 Jeffrey Leiden was honored with the Forbes Lifetime Achievement in BioPharma Award at the 2020 Forbes Healthcare Summit.{{Cite web|title=A Tribute to Jeffrey Leiden: Forbes Lifetime Achievement in BioPharma Award {{!}} 2020 Forbes Healthcare Summit|url=https://www.forbes.com/video/6215745083001/a-tribute-to-jeffrey-leiden-forbes-lifetime-achievement-in-biopharma-award--2020-forbes-healthcare-summit/|access-date=2020-12-15|website=Forbes|language=en}}

Leiden also served in 2016 as co-chairman of the Massachusetts’s Governor’s Digital Healthcare Council;{{cite news |last1=Wood |first1=Colin |title=Massachusetts announces Digital Healthcare Council |url=https://statescoop.com/massachusetts-announces-digital-healthcare-council/ |publisher=Statescoop |date=22 November 2016}} is a member of the Governor's Task Force on Artificial Intelligence;{{cite news |last1=Solis |first1=Steven |title=Massachusetts taps tech leaders, Boston officials for AI task force |url=https://www.axios.com/local/boston/2024/02/14/massachusetts-ai-task-force-members-chosen |publisher=Axios |date=14 February 2024}}{{cite news |title=Massachusetts Establishes Task Force to Scale AI Adoption in the State |url=https://www.cdomagazine.tech/aiml/massachusetts-establishes-task-force-to-scale-ai-adoption-in-the-state |publisher=cdo magazine |date=7 March 2024}}{{cite news |title=Governor Healey Signs Executive Order Establishing Artificial Intelligence (AI) Strategic Task Force |url=https://www.mass.gov/news/governor-healey-signs-executive-order-establishing-artificial-intelligence-ai-strategic-task-force |publisher=Mass.gov |date=14 February 2024}} and the Governor’s STEM Advisory Council.{{cite news |title=Healey-Driscoll Administration Announces 2024 STEM Summit |url=https://www.mass.gov/news/healey-driscoll-administration-announces-2024-stem-summit |publisher=Mass.gov |date=22 April 2024}}

In 2018 he was honored with the "New Englander of the Year Award" by the New England Council.{{cite news |title=The New England Council Annual Dinner 2018 |url=https://www.conventures.com/portfolio/new-england-council-annual-dinner-2018/ |publisher=Conventures |date=2018}}{{cite news |title=New England Council hosts annual New Englander of the Year awards |url=https://billbrettboston.com/new-england-council-hosts-annual-new-englander-of-the-year-awards/ |publisher=Bill Bret Boston |date=13 October 2018}}

Leiden was ranked 13th on Forbes' list of most innovative leaders for 2019, the highest-ranking leader in the healthcare/biotech sector.{{Cite web|url=https://www.forbes.com/lists/innovative-leaders/|title=America's Most Innovative Leaders|website=Forbes|language=en|access-date=2019-09-10}}

He is trustee of the Boston Symphony Orchestra.{{Cite web|title=Boston Symphony Orchestra concert program, Subscription Series, Season 139 (2019–2020), Week 6, page 5|url=https://collections.bso.org/digital/collection/PROG/id/769726/|website=collections.bso.org|language=en|access-date=2020-05-05}}

Leiden is a member of the MIT Presidential CEO Advisory Board.{{Cite web|url=https://www.vrtx.com/our-company/leadership/jeffrey-leiden|title=Jeffrey Leiden, M.D., Ph.D.|website=Vertex}}

In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of J.P. Morgan.{{cite news |last1=Bayer |first1=Max |title=J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference |url=https://www.fiercebiotech.com/biotech/jp-morgan-launches-new-life-sciences-private-equity-arm-fund-breakthrough-biopharmas |publisher=Fierce Biotech |date=3 November 2022}}

He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022.{{cite web |title=MACP |url=https://www.masscompetes.org/about-us |website=masscompetes.org}}{{cite web |title=Jeffrey Leiden, MD, PhD |url=https://www.vrtx.com/our-company/leadership/jeffrey-leiden/ |website=Vrtx.com}}

In December 2017, Leiden and his wife Lisa established a professorship in translational medicine at the Brigham and Women’s Hospital and Harvard Medical School.{{cite web| url =https://hms.harvard.edu/news/bench-bedside|title=Bench to Bedside|publisher=Harvard Medical School|date =November 1, 2017}} The Leidens are also major donors to the Museum of Fine Arts, Boston, Ariadne Labs and the Bottom Line Foundation.{{cite web| url =https://www.mfa.org/future-is-now/new-investments|title=The Future is Now: New Investments|publisher=Museum of Fine Arts, Boston|accessdate =May 24, 2018}}

{{reflist}}

{{Authority control}}

{{DEFAULTSORT:Leiden, Jeffrey}}

Category:Living people

Category:American health care chief executives

Category:Harvard Medical School people

Category:University of Chicago alumni

Category:Year of birth missing (living people)

Category:Chief executives in the pharmaceutical industry

Category:University of Michigan faculty

Category:Members of the National Academy of Medicine